Nuro, Inc. is a technology company based in Mountain View, California, that specializes in the development of self-driving vehicles specifically designed for local goods transportation. Incorporated in 2016, Nuro aims to transform local commerce through its fleet of fully autonomous, electric vehicles that facilitate the delivery of a wide range of products, including food and pharmaceuticals. By enabling retailers to efficiently and safely deliver goods to customers, Nuro enhances the convenience of local commerce and meets the growing demand for autonomous delivery solutions.
Arbor Biotechnologies
Series C in 2025
Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.
Epirus, Inc. is a technology company based in Hawthorne, California, specializing in the design and development of advanced defense systems that utilize artificial intelligence and directed energy. Founded in 2018, the company focuses on creating solid-state, software-defined high-power microwave solutions aimed at countering unmanned aircraft systems and other asymmetric threats. Its flagship product, ELECTROMAGNETIC PULSE, serves as a counter-infrastructure solution that can simultaneously target multiple threats, effectively neutralizing drones and swarms. By integrating AI and machine learning with advanced electronics, Epirus enhances the detection and tracking of objects of interest, offering innovative capabilities in electronic warfare and power management for both defense and commercial sectors.
Eikon Therapeutics
Series D in 2025
Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.
Clear Labs
Series D in 2025
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dxâ„¢ and Clear Safetyâ„¢, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Outset Medical
Post in 2025
Outset Medical is a medical technology company that develops innovative hemodialysis systems. Founded in 2003, it specializes in the Tablo dialysis machine, designed for both acute and chronic settings. The Tablo system features integrated water purification, on-demand dialysate production, software connectivity capabilities, and sensor-based automation.
SandboxAQ
Series E in 2024
SandboxAQ specializes in developing advanced artificial intelligence and quantum technology products. The company integrates expertise from diverse fields to create Large Quantitative Models and AI sensing applications, focusing on practical solutions for industries such as financial services, healthcare, and telecommunications.
nChroma Bio
Venture Round in 2024
nChroma Bio is a biotechnology company specializing in targeted genetic medicine. It operates an integrated product engine for safe, accurate, and targeted in vivo administration, aiming to overcome limitations of current genetic medicine techniques. The company focuses on liver-targeted therapies, initially for chronic hepatitis B and D, leveraging epigenetics to enable precise and specific gene regulation. This approach allows for therapies with programmable tissue specificity, potentially offering durable and targeted cures for the liver and other organs.
Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.
Seaport Therapeutics
Series B in 2024
Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines in areas of high patient need. Its innovative approach aims to improve oral bioavailability, thereby reducing side effects such as hepatotoxicity and enhancing patients' quality of life with neuropsychiatric disorders.
Lightmatter
Series D in 2024
Founded in 2017 and based in Boston, Lightmatter is an artificial intelligence hardware company that specializes in integrated optical technology. It designs photonic chips to enable data processing and communication through light signals, aiming to improve efficiency and scalability for AI data centers.
Form Energy
Series F in 2024
Form Energy, Inc. is a company focused on developing long-duration energy storage systems aimed at transforming the electric grid by enabling the reliable use of renewable energy sources such as wind and solar. Established in 2017 and based in Somerville, Massachusetts, Form Energy is known for its innovative iron-air battery technology, which allows for the storage of electricity over extended periods, making renewable energy more dispatchable throughout the year. This technology not only helps to replace conventional fossil fuel-based generation but also enhances transmission capacity without the need for new infrastructure. By facilitating deep decarbonization of the electric system, Form Energy plays a significant role in reducing carbon emissions and promoting a sustainable energy future.
KoBold Metals
Series C in 2024
KoBold Metals specializes in global mineral exploration for battery materials. It combines geological expertise with advanced data analytics and machine learning to identify prospective cobalt sources, supporting the electric vehicle revolution.
Aktis Oncology
Series B in 2024
Aktis Oncology is a biotechnology company developing targeted radiopharmaceuticals for treating various solid tumor cancers. Its proprietary platforms generate tumor-targeting agents with optimal properties for alpha radiotherapy, ensuring high tumor penetration and long residence time to maximize tumor elimination while minimizing side effects.
ArsenalBio
Series C in 2024
ArsenalBio is a programmable cell therapy company established in 2019, focused on developing and commercializing innovative immune cell therapies, particularly for cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create multifunctional T-cell therapies. ArsenalBio's approach involves the precise insertion of large synthetic DNA sequences, enabling the generation of next-generation autologous T-cell therapies. By integrating these cutting-edge methods, ArsenalBio aims to enhance the effectiveness and safety of immune cell therapies, reduce costs for healthcare providers, and improve market access, ultimately broadening patient outcomes and making these therapies more widely available.
MBX Biosciences
Series C in 2024
MBX Biosciences is a biotechnology company focused on developing therapies for endocrine and metabolic disorders, emphasizing rare endocrine diseases with limited treatment options. It pursues discovery, development, and commercialization of first-in-class peptide therapeutics that modulate glandular hormone signaling. MBX has developed a proprietary Precision Endocrine Peptide platform to engineer peptides with extended time-action profiles and consistent drug exposure, aiming to overcome limitations of traditional peptide therapies and improve disease management. Based in Carmel, Indiana, the company advances novel peptide programs through clinical development to address unmet medical needs in endocrine and metabolic disorders.
Kestra Medical Technologies
Private Equity Round in 2024
Kestra Medical Technologies, Inc. is a company that specializes in developing and manufacturing wearable medical devices aimed at monitoring and managing acute medical conditions. Founded in 2014 and headquartered in Kirkland, Washington, the company offers solutions that enable the collection, communication, and storage of patient performance data, facilitating both real-time and retrospective analysis. Among its key products are wearable cardioverter defibrillators designed to prevent sudden cardiac death and aid in the recovery of at-risk cardiac patients. By focusing on intuitive and mobile diagnostic and therapeutic technologies, Kestra Medical Technologies strives to enhance patient care and support healthcare teams in effectively managing patient health.
Waymo is a self-driving technology company dedicated to improving mobility. Established from Google's labs in 2009, Waymo aims to make transportation safer and easier by developing advanced software and sensor technologies. The company achieved the world's first fully self-driven trip on public roads in 2015, using cars without steering wheels or pedals. Today, Waymo continues to refine its technology through extensive simulation testing and real-world driving across multiple cities.
Clio is a web-based practice management system designed for solo practitioners and small law firms. It offers tools for client collaboration, case tracking, billing, and communication.
Element Biosciences
Series D in 2024
Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.
PolicyBazaar Insurance Brokers Private Limited is an online platform based in Gurugram, India, that offers a range of insurance services, including life, health, car, two-wheeler, travel, and home insurance. Founded in 2014, the company provides a comparison portal and mobile application that enable users to analyze and compare various insurance products based on coverage, premiums, benefits, and exclusions. By doing so, PolicyBazaar helps consumers make informed decisions regarding their insurance needs. The platform also includes tools and calculators to assist users in estimating their insurance requirements. With a focus on creating awareness about financial impacts related to death, disease, and damage, PolicyBazaar generates the majority of its revenue from its insurance services segment, which includes insurance broker services.
Sila is a battery materials company founded in 2011 and headquartered in California, United States. It specializes in the production of energy-density lithium-ion batteries designed for electric vehicles, consumer electronics, and automotive original equipment manufacturers (OEMs). Sila focuses on enhancing energy storage solutions by developing supercharged battery materials that improve performance and longevity. Its products aim to facilitate the mass adoption of affordable, long-range electric vehicles while maintaining high standards of quality control, safety, and cycle life. By collaborating with battery manufacturers, Sila supports commercial cell production, driving innovation and efficiency in the battery technology sector.
Kardium
Private Equity Round in 2024
Founded in 2007, Kardium specializes in advanced medical solutions for atrial fibrillation treatment. Its flagship product is The Globe Mapping and Ablation System, offering single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation using a single catheter.
CARGO Therapeutics
Post in 2024
CARGO Therapeutics is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies to overcome cancer treatment resistance and access barriers. The company focuses on addressing limitations of approved autologous CAR T therapies, including manufacturing constraints, long turnaround times, and reimbursement challenges, to broaden patient access to potentially curative treatments. Its programs aim to deliver novel solutions that improve cancer treatment outcomes and patient experience. One of its product candidates, CRG-023, is a tri-specific CAR T designed to overcome relapse by targeting multiple B-cell antigens (CD19, CD20, CD22) and addressing mechanisms such as antigen loss, insufficient co-stimulation, and T cell exhaustion.
BrightView is a leading provider of commercial landscaping services in the United States. With over 18,000 employees, they offer a range of services including landscape maintenance, enhancements, tree care, and landscape development for various properties such as corporate campuses, public parks, healthcare facilities, educational institutions, and golf courses.
Bluejay Therapeutics
Series C in 2024
Bluejay Therapeutics is a private biopharmaceutical company focused on developing curative treatments for infectious and liver diseases. Its initial program targets chronic hepatitis B, a widespread infection with unmet medical need, using two approaches: fully human IgG1 monoclonal antibodies against hepatitis B surface antigen and oral small-molecule inhibitors of HBsAg. The aim is to reduce viral surface antigen and restore adaptive immunity, potentially achieving a functional cure for HBV and enabling patients to regain immune control of infection. The company’s work also contemplates extending its approach to other viral liver diseases, including chronic hepatitis D.
Endeavor BioMedicines
Series C in 2024
Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.
Obsidian Therapeutics
Series C in 2024
Founded in 2015 and based in Cambridge, Massachusetts, Obsidian Therapeutics develops next-generation controllable cell and gene therapies designed to extend adoptive immunotherapy to every cancer patient. Its innovative approach uses pharmacologic operating systems to precisely control protein activity in cells, enabling physicians to improve upon current cell therapies using simple, safe, orally-active marketed drugs.
Sionna Therapeutics
Series C in 2024
Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function.
In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.
FogPharma
Series E in 2024
FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.
Lambda specializes in deep-learning infrastructure, offering cloud technology, servers, and workstations pre-configured with common ML frameworks. This enables clients to simplify and accelerate the training and deployment of deep learning models, empowering AI engineers to construct, test, and deploy AI products efficiently and securely.
Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.
ProfoundBio
Series B in 2024
ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.
Lilac Solutions
Series C in 2024
Lilac Solutions, Inc. is a mining technology company based in Oakland, California, specializing in lithium extraction technology. Founded in 2015, the company develops innovative solutions that utilize ion-exchange theory to absorb lithium from brine deposits. This technology includes ion exchange beads and continuous brine processing systems, which enable lithium producers to enhance project development, increase lithium recovery, and optimize operations. Lilac Solutions aims to support industries such as electric vehicles and renewable energy storage by providing methods that reduce both costs and environmental impact associated with lithium production.
Odyssey Therapeutics
Series C in 2023
Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.
RefleXion Medical
Venture Round in 2023
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.
Apiture
Venture Round in 2023
Apiture, Inc. is a financial technology company that specializes in developing digital banking solutions for banks and credit unions across the United States. Founded in 2017 and headquartered in Wilmington, North Carolina, with an additional office in Austin, Texas, Apiture offers products such as Apiture Open, which facilitates the opening of checking, savings, CDs, and loan accounts, and Apiture Xpress, an integrated digital banking solution tailored for both consumer and business account holders. The company focuses on empowering financial institutions by providing advanced software that enhances their ability to serve customers efficiently and effectively in today’s digital landscape. Through its API-driven approach, Apiture aims to streamline development processes and enable innovative banking solutions that meet the evolving needs of clients and their customers. Apiture operates as a subsidiary of First Data Corporation and maintains a strategic alliance with DefenseStorm, Inc.
Stash
Convertible Note in 2023
Stash develops a personal finance application to combine banking, investing, and advice into one platform. Its application's services include personal investment accounts, retirement accounts, and custodial accounts for minors. It also provides the option to buy fractional shares of stocks, bonds, and funds with no add-on trading commissions to help users save small sums of money and make micro-investments.
Generate Biomedicines
Series C in 2023
Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.
Databricks
Series I in 2023
Databricks offers a unified data analytics platform that simplifies data integration, enables real-time experimentation, and facilitates robust deployment of production applications for developers and data scientists. Serving diverse industries worldwide, Databricks' platform supports collaborative data science, machine learning workflows, and integrates with various cloud services.
Sortera Technologies
Series C in 2023
Sortera Alloys manufactures low-cost, high-quality metal alloys for domestic manufacturing using its artificial intelligence technology.
Sortera Alloys is a company based in Fort Wayne, Indiana, and was established in 2020.
Redwood Materials
Series D in 2023
Founded by JB Straubel in Nevada, Redwood Materials specializes in recycling lithium-ion batteries and electronics. It develops processes to extract and refine key materials like lithium, nickel, cobalt, and copper, creating a circular supply chain for electric vehicles and energy storage systems. The company aims to reduce environmental impact and lower production costs by recycling end-of-life products.
Rapport Therapeutics
Series B in 2023
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for neurological disorders. The company focuses on creating transformational small-molecule therapies aimed at patients with central nervous system conditions. Leveraging foundational research in neuronal receptor biology, Rapport Therapeutics maps and targets specific neuronal receptor complexes, which are complex assemblies of proteins that include principal receptor subunits and receptor-associated proteins. These receptor-associated proteins are essential for regulating receptor expression and functionality, allowing the company to innovate in the treatment of neurological diseases.
Genesis Therapeutics
Series B in 2023
Founded in 2019, Genesis Therapeutics is a biotechnology company based in South San Francisco, California. It specializes in developing small molecule drug candidates for treating debilitating disorders using artificial intelligence-driven platforms.
ADARx Pharmaceuticals
Series C in 2023
ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.
KoBold Metals
Series B in 2023
KoBold Metals specializes in global mineral exploration for battery materials. It combines geological expertise with advanced data analytics and machine learning to identify prospective cobalt sources, supporting the electric vehicle revolution.
Retiree Income
Acquisition in 2023
Retiree Income is a company dedicated to enhancing the financial well-being of retirees and those approaching retirement. The firm focuses on developing retirement income planning software that aims to maximize after-tax income and bequest value over a client's lifetime. By utilizing advanced analytic engines, the software offers personalized income and tax-efficient withdrawal strategies, along with optimal Social Security claiming options. This approach empowers clients to make informed financial decisions, ultimately improving their ability to manage and optimize retirement resources effectively. Retiree Income is committed to providing smarter and more tailored solutions for individuals navigating retirement planning.
Ring Therapeutics
Series C in 2023
Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.
VerAI Discoveries
Series A in 2023
VerAI Discoveries employs AI and machine learning to identify hidden mineral deposits. It focuses on underexplored areas with favorable mining conditions, enhancing discovery probabilities while reducing economic risks. The company collaborates with industry investors and explorers to develop a global portfolio of base and precious metal targets, contributing to the global critical minerals supply.
Chroma Medicine
Series B in 2023
Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.
CARGO Therapeutics
Series A in 2023
CARGO Therapeutics is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies to overcome cancer treatment resistance and access barriers. The company focuses on addressing limitations of approved autologous CAR T therapies, including manufacturing constraints, long turnaround times, and reimbursement challenges, to broaden patient access to potentially curative treatments. Its programs aim to deliver novel solutions that improve cancer treatment outcomes and patient experience. One of its product candidates, CRG-023, is a tri-specific CAR T designed to overcome relapse by targeting multiple B-cell antigens (CD19, CD20, CD22) and addressing mechanisms such as antigen loss, insufficient co-stimulation, and T cell exhaustion.
Mirion Technologies
Post in 2023
Mirion Technologies specializes in detection, measurement, analysis, and monitoring solutions for the nuclear, defense, medical, and research sectors. The company leverages its expertise in ionizing radiation to benefit humanity while adhering to stringent regulatory standards.
FogPharma
Series D in 2022
FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.
Jetti Resources
Series D in 2022
Founded in 2014, Jetti Resources specializes in hydrometallurgical technology for extracting metals from mineral ores. Its proprietary catalytic process is used to efficiently recover copper from low-grade primary sulfides like chalcopyrite, making it a cost-effective and environmentally responsible solution.
Celonis is a company that specializes in execution management, focusing on optimizing and analyzing business processes across various industries, including production, human resources, and logistics. Its core product, the Celonis Execution Management System (EMS), utilizes advanced process mining technology to enhance productivity and streamline operations. The EMS provides a comprehensive suite of tools and applications, including Celonis Studio, designed for business executives and users to effectively manage execution across analytics, strategy, planning, and automation. By offering unique software solutions, Celonis enables organizations to improve process transparency and efficiency, ultimately unlocking their full execution capacity.
Kymera Therapeutics
Post in 2022
Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.
Cleerly is a healthcare company focused on transforming the management of coronary artery disease through innovative digital care pathways aimed at preventing heart attacks. By combining advanced clinical science with state-of-the-art artificial intelligence, Cleerly develops a platform that delivers actionable clinical insights for all stakeholders involved in heart care. This platform employs a non-invasive approach to analyze and characterize plaque buildup in coronary arteries, allowing healthcare providers to better identify at-risk patients and facilitate early treatment. Cleerly's data-driven solutions not only enhance the evaluation of cardiovascular disease but also aim to improve patient heart health while delivering value to the healthcare system.
Delfi Diagnostics
Series B in 2022
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.
YuLife is a technology-driven insurance company founded in 2016 and headquartered in London. The company aims to inspire individuals and transform financial products into a force for good by integrating gamification and behavioral science into its offerings. YuLife provides life and medical insurance plans while promoting wellness by encouraging users to engage in health-related activities such as walking and meditation. Participants can earn rewards, including air miles, vouchers, and gift cards, which are designed to support their financial, emotional, and physical well-being. By focusing on healthy living, YuLife enables businesses to insure their employees while allowing individuals to reap the benefits of a healthier lifestyle.
Flexe, Inc. operates a cloud-based warehousing services marketplace that connects organizations needing additional warehousing and fulfillment services with those that have excess capacity. Founded in 2013 and headquartered in Seattle, the company specializes in omnichannel logistics, providing solutions for eCommerce fulfillment, retail distribution, same-day delivery, and network capacity. By integrating technology with an open logistics network, Flexe enables retailers, wholesalers, manufacturers, and logistics companies to optimize their operations, address inventory overflow, and streamline material handling. This approach allows clients to enhance their distribution networks by accessing affordable warehouse spaces, thereby maximizing revenue potential while maintaining operational efficiency.
Senti Biosciences
Post in 2022
Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.
Odyssey Therapeutics
Series B in 2022
Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.
Convoy operates an online marketplace for digital freight network services. It connects shippers with local and regional trucks for moving goods efficiently, offering real-time tracking via its mobile app. Founded in 2015, Convoy aims to optimize the trucking industry by reducing waste and emissions.
Tessera Therapeutics
Series C in 2022
Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.
Sionna Therapeutics
Series B in 2022
Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function.
In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.
Cross River Bank
Series D in 2022
Cross River Bank combines traditional banking with innovative technologies to create compliant financial solutions for fintech companies. It offers personal and corporate banking services, direct lending loans, marketplace lender solutions, flash disbursements, and financial technology solutions.
SandboxAQ
Series D in 2022
SandboxAQ specializes in developing advanced artificial intelligence and quantum technology products. The company integrates expertise from diverse fields to create Large Quantitative Models and AI sensing applications, focusing on practical solutions for industries such as financial services, healthcare, and telecommunications.
PrognomiQ
Venture Round in 2022
PrognomiQ is a technology company focused on transforming early disease detection and treatment through multi-omics data. It generates proteomic, genomic, and metabolomic data to provide insights into complex diseases and to improve patient outcomes. The company develops advanced test products that apply multi-omics data to detect cancers and other conditions earlier, complementing traditional diagnostics and supporting monitoring of disease recurrence. By integrating proteomic data with broader health data, PrognomiQ aims to enable clinicians to diagnose more accurately and tailor interventions, ultimately advancing preventive and precision medicine.
RefleXion Medical
Venture Round in 2022
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.
Rigetti Computing
Post in 2022
Rigetti Computing is a full-stack quantum computing company that designs, manufactures, and deploys quantum integrated circuits in low-temperature environments. It develops control systems for quantum logic operations and software to integrate its systems into existing cloud infrastructure. The company focuses on near-term applications in computational chemistry and machine learning, offering the world's first full-stack programming and execution environment for quantum/classical computing.
Saluda Medical
Private Equity Round in 2022
Saluda Medical is a medical device company specializing in closed-loop neuromodulation therapies for chronic neurological conditions. Founded in 2010 and headquartered in Australia, the company develops innovative devices like Evoke, designed to optimize neural stimulation based on real-time feedback.
CelLink designs and manufactures high-conductance, large-area flexible circuits and backplanes for power electronics and solar applications. The company develops flexible conductive backplanes that integrate busing, fusing, voltage and temperature monitoring into a single circuit, enabling efficient power and data transmission. Based in Belmont, California, CelLink serves applications including batteries, LEDs, wire harnessing, and solar cells, aiming to provide reliable, scalable power-management solutions at an affordable price.
Epirus, Inc. is a technology company based in Hawthorne, California, specializing in the design and development of advanced defense systems that utilize artificial intelligence and directed energy. Founded in 2018, the company focuses on creating solid-state, software-defined high-power microwave solutions aimed at countering unmanned aircraft systems and other asymmetric threats. Its flagship product, ELECTROMAGNETIC PULSE, serves as a counter-infrastructure solution that can simultaneously target multiple threats, effectively neutralizing drones and swarms. By integrating AI and machine learning with advanced electronics, Epirus enhances the detection and tracking of objects of interest, offering innovative capabilities in electronic warfare and power management for both defense and commercial sectors.
Endeavor BioMedicines
Series B in 2022
Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.
Eikon Therapeutics
Series B in 2022
Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.
SalioGen Therapeutics
Series B in 2022
SalioGen Therapeutics develops curative therapies for inherited disorders using its Exact DNA Integration Technology (EDIT) platform. EDIT employs proprietary mammal-derived enzymes called Saliogase, enabling non-viral delivery of genes of any size and offering significant manufacturing advantages.
DNA Script
Series C in 2022
DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.
Pardes Biosciences
Post in 2021
Pardes Biosciences is a clinical-stage biopharmaceutical company focused on addressing significant health challenges, particularly those posed by viral infections such as COVID-19. Utilizing modern reversible-covalent chemistry, the company is dedicated to discovering and developing novel oral drug candidates. Its lead product, PBI-0451, is an oral antiviral designed to treat and prevent infections caused by SARS-CoV-2, the virus responsible for COVID-19. Pardes Biosciences aims to enhance patient access to effective treatments, catering to both adult and pediatric populations, while striving to provide convenient and accessible options for those affected by life-threatening viral infections. The company is committed to contributing to global health solutions and improving patient outcomes.
Airtable is a cloud-based software company that provides a no-code platform for creating and sharing relational databases and custom applications. The platform enables users to organize data, automate workflows, and build flexible templates for tasks such as project tracking, inventory management, and CRM, without coding. It supports collaboration across teams and can incorporate artificial intelligence features to streamline processes. Airtable serves organizations across various industries enabling teams to tailor software tools to their workflows without traditional development resources.
Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.
Grab is a Southeast Asia-based mobile platform that integrates ride-hailing, food and grocery delivery, and financial services, connecting drivers, merchants, and customers through a single app. It operates in Singapore, Indonesia, the Philippines, Malaysia, Thailand, Vietnam, and Myanmar, and holds a leading market share in ride-hailing and food delivery, with 89% of revenue derived from these core businesses. The company also offers payments, consumer loans, and enterprise financial services. It charges commissions to both riders and merchants as it links them with consumers. Founded in 2012 by Anthony Tan and Tan Hooi Ling, Grab is headquartered in Singapore and maintains offices in Seattle, Beijing, Bangalore, Jakarta, and Vietnam. In 2024, Singapore, Indonesia, and Malaysia together contributed more than 70% of revenue.
Generate Biomedicines
Series B in 2021
Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.
Farmers Business Network
Series G in 2021
Farmers Business Network is an independent agricultural technology platform that empowers farmers worldwide. It facilitates a farmer-to-farmer network, providing data-driven agronomic insights and tools for confident decision-making to ensure the economic viability of farms while promoting sustainable practices.
Chroma Medicine
Series A in 2021
Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.
Arbor Biotechnologies
Series B in 2021
Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.
Color is a healthcare technology company that offers a comprehensive platform for population health management, facilitating equitable and accessible healthcare delivery. The company specializes in large-scale health initiatives, providing solutions that include population genomics programs and high-throughput testing services, such as those for COVID-19. By centralizing essential healthcare capabilities, Color enables businesses, schools, and state public health departments to implement effective preventive health programs, regardless of the geographical distribution of their populations. Its innovative approach addresses various healthcare logistics challenges, streamlining processes related to testing, screening, treatment, and referrals, while creating diverse market opportunities and revenue streams for clinical teams.
Socure develops digital identity verification solutions using artificial intelligence and machine learning. Its platform authenticates identities in real-time from various online/offline sources, automating customer identification program (CIP), know your customer (KYC), and anti-money laundering (AML) compliance initiatives.
Nextdoor operates a social networking platform connecting neighbors globally, fostering local conversations and community support. It offers services like Help Map to assist vulnerable residents during crises. The company is headquartered in San Francisco with operations across multiple countries.
Aurora Innovation develops advanced software and hardware products for self-driving vehicles, aiming to transform the movement of people and goods. Founded in 2016 and headquartered in Palo Alto, California, the company operates additional offices in the Bay Area, Bozeman, Pittsburgh, and Dallas. Its primary offering, the Aurora Driver, is a scalable self-driving system capable of operating various vehicle types, including freight-hauling trucks and ride-hailing passenger vehicles. This technology supports Aurora's driver-as-a-service products, Aurora Horizon and Aurora Connect, catering to trucking and ride-hailing sectors. By integrating rigorous engineering with applied machine learning, Aurora Innovation seeks to create a comprehensive transportation ecosystem that connects automakers, logistics services, and mobility providers.
Nuro, Inc. is a technology company based in Mountain View, California, that specializes in the development of self-driving vehicles specifically designed for local goods transportation. Incorporated in 2016, Nuro aims to transform local commerce through its fleet of fully autonomous, electric vehicles that facilitate the delivery of a wide range of products, including food and pharmaceuticals. By enabling retailers to efficiently and safely deliver goods to customers, Nuro enhances the convenience of local commerce and meets the growing demand for autonomous delivery solutions.
Rad Power Bikes
Series D in 2021
Rad Power Bikes LLC, based in Seattle, Washington, is North America's largest electric bike brand, incorporated in 2015. The company designs and manufactures electric bicycles suitable for both on and off-road use, offering feature-rich and affordable options tailored to individual needs. In addition to its bikes, Rad Power Bikes provides a range of accessories, including bags, fenders, racks, and safety products, as well as replacement parts like batteries and tires. Utilizing a direct-to-consumer sales model, the company has experienced rapid growth and aims to democratize electric biking, making energy-efficient transportation accessible and enjoyable for a wide audience. With a team of over 700 employees, Rad Power Bikes is committed to transforming the landscape of electric mobility.
Oak Hill Advisors
Acquisition in 2021
Founded in 1987, Oak Hill Advisors is a global investment firm specializing in credit markets. It manages various credit-focused funds, investing primarily in leveraged loans, high yield bonds, structured products, distressed securities, and turnaround investments across North America, Europe, and other geographies.
Trumid
Venture Round in 2021
Trumid Financial LLC is a financial technology company based in New York that specializes in electronic trading solutions for the credit market. Founded in 2014, Trumid operates the Trumid Market Center, an electronic trading network specifically designed for corporate bonds, and offers Trumid Bond Stream, a tool that provides TRACE pricing data. The company focuses on enhancing the credit trading experience by integrating advanced technology with market expertise, facilitating direct access to liquidity and valuable market intelligence for professionals in the corporate bond sector. Additionally, Trumid Labs leverages data science to manage its network and provide bond price lookup services, enabling participants to make informed trading decisions. Trumid operates as a subsidiary of Trumid Holdings LLC.
Honor is a leading senior care network and technology platform that focuses on enhancing the quality of life for older adults and their families. Founded in 2014 by Cameron Ring, Monica Lo, Sandy Jen, and Seth Sternberg in San Francisco, California, Honor has established itself as a pioneer in the home care industry. The company offers expert in-home care services for seniors, leveraging an integrated system of third-party care providers. By combining scalable workforce management with personalized care, Honor enables older adults to live safely and comfortably in their own homes. In 2021, Honor expanded its reach by acquiring Home Instead, enhancing its capabilities through a global network and a relationship-based care model. This strategic move positions Honor to address the evolving needs of aging adults and professional caregivers worldwide.
Coalition
Series E in 2021
Coalition provides comprehensive insurance coverage and proactive cybersecurity tools to manage and mitigate cyber risks for businesses across various industries. Backed by leading global insurers, Coalition offers its services in the US and Canada, with a global workforce operating from digital hubs worldwide.
Ginkgo Bioworks
Post in 2021
Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
Canva
Venture Round in 2021
Canva is a global provider of graphic design software solutions. Founded in 2012, it offers an online platform that enables users to create designs for presentations, social media graphics, and more using a wide range of layouts, images, filters, icons, shapes, and fonts. Its user-friendly interface democratizes design by making professional-quality graphics accessible to all.
Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.
Checkr is a technology company that builds platforms for the background check industry. It provides screening services such as social security number trace, criminal record checks, driving records, verifications, drug tests, and credit checks, along with continuous monitoring and security infrastructure. The company offers an API and Checkr Connect IDV to integrate identity verification with background checks, enabling faster and more transparent hiring decisions. It serves multiple sectors, including financial services, retail and hospitality, healthcare, higher education, on-demand economy platforms, manufacturing, software and technology, and contact centers and peer-to-peer marketplaces. Founded in 2014, Checkr is headquartered in San Francisco.
Founded in 1999, SomaLogic specializes in the discovery, development, and commercialization of life science research tools and clinical diagnostic products centered around its proprietary SOMAmer/SOMAscan technology. This platform enables protein measurement at scale, facilitating biomarker discovery for various diseases, drug development, and clinical diagnostics.